OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+1.9%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$681M
AUM Growth
+$681M
(-11%)
Cap. Flow
-$30.5M
Cap. Flow
% of AUM
-4.47%
Top 10 Holdings %
Top 10 Hldgs %
54.41%
Holding
74
New
15
Increased
15
Reduced
15
Closed
16
Top Buys
| 1 |
BridgeBio Pharma
BBIO
|
$36M |
| 2 |
AUTL
Autolus Therapeutics
AUTL
|
$12.1M |
| 3 |
Disc Medicine
IRON
|
$11M |
| 4 |
Keros Therapeutics
KROS
|
$9.69M |
| 5 |
MacroGenics
MGNX
|
$9.41M |
Top Sells
| 1 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
$41.5M |
| 2 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$21.7M |
| 3 |
TG Therapeutics
TGTX
|
$20.2M |
| 4 |
Cardiff Oncology
CRDF
|
$10.1M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$8.93M |
Sector Composition
| 1 | Healthcare | 98.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $106M | 15.62% | 6,480,000 -30,000 | -0.5% | -$492K |
|
|
CMRX
2
DELISTED
Chimerix, Inc.
CMRX
| $43.3M | 6.36% | 4,490,000 +533,500 | +13% | +$5.14M |
|
3
Protara Therapeutics
TARA
$120M
| $40.3M | 5.92% | 2,558,472 | – | – |
|
|
4
BridgeBio Pharma
BBIO
$9.89B
| $36M | 5.28% | +583,767 | New | +$36M |
|
5
Codexis
CDXS
$246M
| $32M | 4.71% | 1,400,000 | – | – |
|
6
Eton Pharmaceutcials
ETON
$464M
| $29.6M | 4.34% | 4,040,000 | – | – |
|
|
7
MacroGenics
MGNX
$112M
| $21.2M | 3.12% | 666,200 +295,600 | +80% | +$9.41M |
|
|
TCON
8
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $20.7M | 3.04% | 2,518,371 | – | – |
|
9
Harrow
HROW
$1.44B
| $20.7M | 3.04% | 3,065,416 | – | – |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $20.3M | 2.98% | 985,000 -7,000 | -0.7% | -$144K |
|
11
Xoma
XOMA
$392M
| $17.9M | 2.62% | 437,500 -17,500 | -4% | -$714K |
|
12
Stereotaxis
STXS
$261M
| $17M | 2.49% | 2,526,500 -494,936 | -16% | -$3.33M |
|
13
Neurogene
NGNE
$264M
| $15.1M | 2.22% | 1,225,000 -161,300 | -12% | -$1.99M |
|
14
Fortress Biotech
FBIO
$76.8M
| $13.7M | 2.01% | 3,875,000 -12,500 | -0.3% | -$44.1K |
|
15
Cytokinetics
CYTK
$4.23B
| $13.5M | 1.98% | 580,000 -2,800 | -0.5% | -$65.1K |
|
|
AUTL
16
Autolus Therapeutics
AUTL
$399M
| $12.1M | 1.78% | +2,112,918 | New | +$12.1M |
|
|
17
Disc Medicine
IRON
$2.07B
| $11M | 1.61% | +810,500 | New | +$11M |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.95M | 1.46% | 222,000 | – | – |
|
19
Seres Therapeutics
MCRB
$166M
| $9.8M | 1.44% | 300,000 -35,312 | -11% | -$1.15M |
|
|
20
Keros Therapeutics
KROS
$618M
| $9.69M | 1.42% | +157,500 | New | +$9.69M |
|
|
CKPT
21
DELISTED
Checkpoint Therapeutics
CKPT
| $9.19M | 1.35% | +2,925,963 | New | +$9.19M |
|
22
ProQR Therapeutics
PRQR
$237M
| $8.61M | 1.27% | +1,303,000 | New | +$8.61M |
|
23
ESSA Pharma
EPIX
$11.4M
| $8.25M | 1.21% | 284,050 | – | – |
|
|
AFIB
24
DELISTED
Acutus Medical, Inc. Common Stock
AFIB
| $8.22M | 1.21% | 614,990 -135,000 | -18% | -$1.8M |
|
|
ADMS
25
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $8.02M | 1.18% | 1,670,600 +182,800 | +12% | +$877K |
|